Skip to main content

Advertisement

SpringerLink
Log in

lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways

  • Review Article
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cancer drug resistance remains a formidable challenge in modern oncology, necessitating innovative therapeutic strategies. The convergence of intricate regulatory networks involving long non-coding RNAs, microRNAs, and pivotal signaling pathways has emerged as a crucial determinant of drug resistance. This review underscores the multifaceted roles of lncRNAs and miRNAs in orchestrating gene expression and cellular processes, mainly focusing on their interactions with specific signaling pathways. Dysregulation of these networks leads to the acquisition of drug resistance, dampening the efficacy of conventional treatments. The review highlights the potential therapeutic avenues unlocked by targeting these non-coding RNAs. Developing specific inhibitors or mimics for lncRNAs and miRNAs, alone or in combination with conventional chemotherapy, emerges as a promising strategy. In addition, epigenetic modulators, immunotherapies, and personalized medicine present exciting prospects in tackling drug resistance. While substantial progress has been made, challenges, including target validation and safety assessment, remain. The review emphasizes the need for continued research to overcome these hurdles and underscores the transformative potential of lncRNA-miRNA interplay in revolutionizing cancer therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Not available.

References

  1. Patterson NR. Cancer drug resistance mechanisms. Columbia: University of Missouri; 2023.

    Google Scholar 

  2. Saw PE, Xu X, Chen J, Song E-W. Non-coding RNAs: the new central dogma of cancer biology. Sci China Life Sci. 2021;64:22–50.

    Article  CAS  PubMed  Google Scholar 

  3. Volovat SR, Volovat C, Hordila I, Hordila D-A, Mirestean CC, Miron OT, Lungulescu C, Scripcariu DV, Stolniceanu CR, Konsoulova-Kirova AA. MiRNA and LncRNA as potential biomarkers in triple-negative breast cancer: a review. Front Oncol. 2020;10:526850.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Shetty A, Venkatesh T, Kabbekodu SP, Tsutsumi R, Suresh PS. LncRNA–miRNA–mRNA regulatory axes in endometrial cancer: a comprehensive overview. Arch Gynecol Obstet. 2022;306:1431–47.

    Article  CAS  PubMed  Google Scholar 

  5. Entezari M, Taheriazam A, Orouei S, Fallah S, Sanaei A, Hejazi ES, Kakavand A, Rezaei S, Heidari H, Behroozaghdam M, et al. LncRNA-miRNA axis in tumor progression and therapy response: an emphasis on molecular interactions and therapeutic interventions. Biomed Pharmacother. 2022;154:113609.

    Article  CAS  PubMed  Google Scholar 

  6. Ashrafizadeh M, Gholami MH, Mirzaei S, Zabolian A, Haddadi A, Farahani MV, Kashani SH, Hushmandi K, Najafi M, Zarrabi A, et al. Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: aew insight to proliferation and metastasis. Life Sci. 2021;270:119006.

    Article  CAS  PubMed  Google Scholar 

  7. Alshahrani SH, Al-Hadeithi ZS, Almalki SG, Malviya J, Hjazi A, Mustafa YF, Alawady AHR, Alsaalamy AH, Joshi S, Alkhafaji AT. LncRNA-miRNA interaction is involved in colorectal cancer pathogenesis by modulating diverse signaling pathways. Pathol Res Pract. 2023;251:154898.

    Article  CAS  PubMed  Google Scholar 

  8. Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013;85:1219–26.

    Article  CAS  PubMed  Google Scholar 

  9. Singh D, Assaraf YG, Gacche RN. Long non-coding RNA mediated drug resistance in breast cancer. Drug Resist Updat. 2022;63:100851.

    Article  CAS  PubMed  Google Scholar 

  10. Gupta SK, Singh P, Ali V, Verma M. Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy. Oncol Rev. 2020;14:448.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, Meerzaman D, Hong KM, Mann F, Dracheva T. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non–small cell lung cancer. Clin Cancer Res. 2005;11:2106–10.

    Article  CAS  PubMed  Google Scholar 

  12. Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. 2016;1:e000060.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Christowitz C, Davis T, Isaacs A, Van Niekerk G, Hattingh S, Engelbrecht A-M. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer. 2019;19:1–10.

    Article  CAS  Google Scholar 

  14. Karran P, Offman J, Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie. 2003;85:1149–60.

    Article  CAS  PubMed  Google Scholar 

  15. Tolomeo M, Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem Anti-Cancer Agents. 2002;2:387–401.

    Article  CAS  PubMed  Google Scholar 

  16. Li Y, Wang Z, Ajani JA, Song S. Drug resistance and cancer stem cells. Cell Commun Signal. 2021;19:1–11.

    Article  Google Scholar 

  17. Damgaci S, Ibrahim-Hashim A, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ. Hypoxia and acidosis: immune suppressors and therapeutic targets. Immunology. 2018;154:354–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Karami Fath M, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Akbari Oryani M, Shakeri F, Nasirzadeh F, Khalesi B, Nabi-Afjadi M. The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022;27:1–25.

    Article  Google Scholar 

  19. Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov. 2020;19:39–56.

    Article  CAS  PubMed  Google Scholar 

  20. Chen W, Ruan M, Zou M, Liu F, Liu H. Clinical significance of non-coding RNA regulation of programmed cell death in hepatocellular carcinoma. Cancers (Basel). 2023;15:4187.

    Article  CAS  PubMed  Google Scholar 

  21. Najafi S, Khatami SH, Khorsand M, Jamali Z, Shabaninejad Z, Moazamfard M, Majidpoor J, Zarch SMA, Movahedpour A. Long non-coding RNAs (lncRNAs); roles in tumorigenesis and potentials as biomarkers in cancer diagnosis. Exp Cell Res. 2022;418:113294.

    Article  CAS  PubMed  Google Scholar 

  22. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17:47–62.

    Article  CAS  PubMed  Google Scholar 

  23. Nojima T, Proudfoot NJ. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics. Nat Rev Mol Cell Biol. 2022;23:389–406.

    Article  CAS  PubMed  Google Scholar 

  24. Li L, Miao H, Chang Y, Yao H, Zhao Y, Wu F, Song X. Multidimensional crosstalk between RNA-binding proteins and noncoding RNAs in cancer biology. Semin Cancer Biol. 2021;75:84–96.

    Article  CAS  PubMed  Google Scholar 

  25. Chen L-L. Linking long noncoding RNA localization and function. Trends Biochem Sci. 2016;41:761–72.

    Article  CAS  PubMed  Google Scholar 

  26. Gandhi M, Caudron-Herger M, Diederichs S. RNA motifs and combinatorial prediction of interactions, stability and localization of noncoding RNAs. Nat Struct Mol Biol. 2018;25:1070–6.

    Article  CAS  PubMed  Google Scholar 

  27. Carlevaro-Fita J, Johnson R. Global positioning system: understanding long noncoding RNAs through subcellular localization. Mol Cell. 2019;73:869–83.

    Article  CAS  PubMed  Google Scholar 

  28. Shah IM, Dar MA, Bhat KA, Dar TA, Ahmad F, Ahmad SM. Long non-coding RNAs: biogenesis, mechanism of action and role in different biological and pathological processes. Noncoding RNA Res. 2022. https://doi.org/10.5772/intechopen.104861.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hulshoff MS, Xu X, Krenning G, Zeisberg EM. Epigenetic regulation of endothelial-to-mesenchymal transition in chronic heart disease: histone modifications, DNA methylation, and noncoding RNAs. Arterioscler Thromb Vasc Biol. 2018;38:1986–96.

    Article  CAS  PubMed  Google Scholar 

  30. Ding M, Liu Y, Liao X, Zhan H, Liu Y, Huang W. Enhancer RNAs (eRNAs): new insights into gene transcription and disease treatment. J Cancer. 2018;9:2334.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Gupta SC, Awasthee N, Rai V, Chava S, Gunda V, Challagundla KB. Long non-coding RNAs and nuclear factor-κB crosstalk in cancer and other human diseases. Biochimica Biophys Acta. 2020;1873:188316.

    CAS  Google Scholar 

  32. Statello L, Guo C-J, Chen L-L, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96–118.

    Article  CAS  PubMed  Google Scholar 

  33. Grüll MP, Massé E. Mimicry, deception and competition: the life of competing endogenous RNAs. Wiley Interdiscipl Rev RNA. 2019;10:e1525.

    Article  Google Scholar 

  34. Chen X, Sun Y, Cai R, Wang G, Shu X, Pang W. Long noncoding RNA: multiple players in gene expression. BMB Rep. 2018;51:280–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Gowthaman U, García-Pichardo D, Jin Y, Schwarz I, Marquardt S. DNA processing in the context of noncoding transcription. Trends Biochem Sci. 2020;45:1009–21.

    Article  CAS  PubMed  Google Scholar 

  36. Böhmdorfer G, Wierzbicki AT. Control of chromatin structure by long noncoding RNA. Trends Cell Biol. 2015;25:623–32.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Yang Y, Wen L, Zhu H. Unveiling the hidden function of long non-coding RNA by identifying its major partner-protein. Cell Biosci. 2015;5:1–10.

    Article  Google Scholar 

  38. Chen Y, Belmont AS. Genome organization around nuclear speckles. Curr Opin Genet Dev. 2019;55:91–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Gonzalez I, Munita R, Agirre E, Dittmer TA, Gysling K, Misteli T, Luco RF. A lncRNA regulates alternative splicing via establishment of a splicing-specific chromatin signature. Nat Struct Mol Biol. 2015;22:370–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Su M, Wang H, Wang W, Wang Y, Ouyang L, Pan C, Xia L, Cao D, Liao Q. LncRNAs in DNA damage response and repair in cancer cells. Acta Biochim Biophys Sin. 2018;50:433–9.

    Article  CAS  PubMed  Google Scholar 

  41. Mao W, Liao Y, Tang L. Long intergenic non-protein coding RNA 173 in human cancers. Cancers (Basel). 2022;14:5923.

    Article  CAS  PubMed  Google Scholar 

  42. Mattick JS, Amaral PP, Carninci P, Carpenter S, Chang HY, Chen L-L, Chen R, Dean C, Dinger ME, Fitzgerald KA. Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023;24:430–47.

    Article  CAS  PubMed  Google Scholar 

  43. Al-Noshokaty TM, Mansour A, Abdelhamid R, Abdellatif N, Alaaeldien A, Reda T, Abdelmaksoud NM, Doghish AS, Abulsoud AI, Elshaer SS. Role of long non-coding RNAs in pancreatic cancer pathogenesis and treatment resistance-A review. Pathol Res Pract. 2023;245:154438.

    Article  CAS  PubMed  Google Scholar 

  44. Zhao M, Wang S, Li Q, Ji Q, Guo P, Liu X. MALAT1: A long non-coding RNA highly associated with human cancers. Oncol Lett. 2018;16:19–26.

    PubMed  PubMed Central  Google Scholar 

  45. Yuan C, Ning Y, Pan Y. Emerging roles of HOTAIR in human cancer. J Cell Biochem. 2020;121:3235–47.

    Article  CAS  PubMed  Google Scholar 

  46. Yu Y, Hann SS. Novel tumor suppressor lncRNA growth arrest-specific 5 (GAS5) in human cancer. Onco Targets Ther. 2019;12:8421.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Al-Rugeebah A, Alanazi M, Parine NR. MEG3: an oncogenic long non-coding RNA in different cancers. Pathol Oncol Res. 2019;25:859–74.

    Article  CAS  PubMed  Google Scholar 

  48. Lim YWS, Xiang X, Garg M, Le MT, Wong AL-A, Wang L, Goh B-C. The double-edged sword of H19 lncRNA: insights into cancer therapy. Cancer Lett. 2021;500:253–62.

    Article  CAS  Google Scholar 

  49. Teppan J, Barth DA, Prinz F, Jonas K, Pichler M, Klec C. Involvement of long non-coding RNAs (lncRNAs) in tumor angiogenesis. Non-coding RNA. 2020;6:42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Liu X, Zhao S, Sui H, Liu H, Yao M, Su Y, Qu P. MicroRNAs/LncRNAs modulate MDSCs in tumor microenvironment. Front Oncol. 2022;12:772351.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yousefi H, Maheronnaghsh M, Molaei F, Mashouri L, Reza Aref A, Momeny M, Alahari SK. Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance. Oncogene. 2020;39:953–74.

    Article  CAS  PubMed  Google Scholar 

  52. Wang Q, Li X, Ren S, Su C, Li C, Li W, Yu J, Cheng N, Zhou C. HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition. Lung Cancer. 2020;147:99–105.

    Article  PubMed  Google Scholar 

  53. Nandwani A, Rathore S, Datta M. LncRNAs in cancer: regulatory and therapeutic implications. Cancer Lett. 2021;501:162–71.

    Article  CAS  PubMed  Google Scholar 

  54. Dastmalchi N, Safaralizadeh R, Nargesi MM. LncRNAs: potential novel prognostic and diagnostic biomarkers in colorectal cancer. Curr Med Chem. 2020;27:5067–77.

    Article  CAS  PubMed  Google Scholar 

  55. Khawar MB, Hamid SE, Jan T, Abbasi MH, Idnan M, Sheikh N. Diagnostic, prognostic and therapeutic potential of long noncoding RNAs in cancer. Mol Biol Rep. 2022;49:2311–9.

    Article  CAS  PubMed  Google Scholar 

  56. Badowski C, He B, Garmire LX. Blood-derived lncRNAs as biomarkers for cancer diagnosis: the good, the bad and the beauty. NPJ Precis Oncol. 2022;6:40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Wang WT, Han C, Sun YM, Chen TQ, Chen YQ. Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. 2019;12:55.

    Article  PubMed  PubMed Central  Google Scholar 

  58. López-Urrutia E, Bustamante Montes LP, de Guevara L, Cervantes D, Pérez-Plasencia C, Campos-Parra AD. Crosstalk between long non-coding RNAs, micro-RNAs and mRNAs: deciphering molecular mechanisms of master regulators in cancer. Front Oncol. 2019;9:669.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Liz J, Portela A, Soler M, Gomez A, Ling H, Michlewski G, Calin GA, Guil S, Esteller M. Regulation of pri-miRNA processing by a long noncoding RNA transcribed from an ultraconserved region. Mol Cell. 2014;55:138–47.

    Article  CAS  PubMed  Google Scholar 

  60. Sun Q, Song YJ, Prasanth KV. One locus with two roles: microRNA-independent functions of microRNA-host-gene locus-encoded long noncoding RNAs. Wiley Interdiscip Rev RNA. 2021;12:e1625.

    Article  CAS  PubMed  Google Scholar 

  61. Sun Q, Tripathi V, Yoon J-H, Singh DK, Hao Q, Min K-W, Davila S, Zealy RW, Li XL, Polycarpou-Schwarz M. MIR100 host gene-encoded lncRNAs regulate cell cycle by modulating the interaction between HuR and its target mRNAs. Nucleic Acids Res. 2018;46:10405–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Zhang C, Zhou Y, Zhang B, Sheng Z, Sun N, Yuan B, Wu X. Identification of lncRNA, miRNA and mRNA expression profiles and ceRNA Networks in small cell lung cancer. BMC Genomics. 2023;24:217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Venkatesh J, Wasson M-CD, Brown JM, Fernando W, Marcato P. LncRNA-miRNA axes in breast cancer: novel points of interaction for strategic attack. Cancer Lett. 2021;509:81–8.

    Article  CAS  PubMed  Google Scholar 

  64. Chen B, Dragomir MP, Yang C, Li Q, Horst D, Calin GA. Targeting non-coding RNAs to overcome cancer therapy resistance. Signal Transduct Target Ther. 2022;7:121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, Amero P, Rodriguez-Aguayo C. Targeting miRNAs and other non-coding RNAs as a therapeutic approach: an update. Noncoding RNA. 2023;9:27.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Di Martino MT, Riillo C, Scionti F, Grillone K, Polerà N, Caracciolo D, Arbitrio M, Tagliaferri P, Tassone P. miRNAs and lncRNAs as novel therapeutic targets to improve cancer immunotherapy. Cancers (Basel). 2021;13:1587.

    Article  PubMed  Google Scholar 

  67. Kong X, Hu S, Yuan Y, Du Y, Zhu Z, Song Z, Lu S, Zhao C, Yan D. Analysis of lncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. J Cancer. 2020;11:3357.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 1937;2019:12.

    Google Scholar 

  69. Du T, Shi Y, Xu S, Wan X, Sun H, Liu B. Long non-coding RNAs in drug resistance of breast cancer. OncoTargets Ther. 2020;13:7075–87.

    Article  CAS  Google Scholar 

  70. Liu Y, Ao X, Wang Y, Li X, Wang J. Long non-coding RNA in gastric cancer: mechanisms and clinical implications for drug resistance. Front Oncol. 2022;12:841411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Chen Y, Zitello E, Guo R, Deng Y. The function of LncRNAs and their role in the prediction, diagnosis, and prognosis of lung cancer. Clin Transl Med. 2021;11:e367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Jin KT, Lu ZB, Lv JQ, Zhang JG. The role of long non-coding RNAs in mediating chemoresistance by modulating autophagy in cancer. RNA Biol. 2020;17:1727–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Orafidiya F, Deng L, Bevan CL, Fletcher CE. Crosstalk between long non coding RNAs, microRNAs and DNA damage repair in prostate cancer: new therapeutic opportunities? Cancers (Basel). 2022;14:755.

    Article  CAS  PubMed  Google Scholar 

  74. Wang T, Ji M, Liu W, Sun J. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma. Comput Struct Biotechnol J. 2023;21:4944–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Zhu J, Chen S, Yang B, Mao W, Yang X, Cai J. Molecular mechanisms of lncRNAs in regulating cancer cell radiosensitivity. Biosci Rep. 2019;39:BSR20190590.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Zou S, Gou X, Wen K. Advances in the role of long non-coding RNAs and RNA-binding proteins in regulating DNA damage repair in cancer cells. Int J Mol Med. 2023;52:1–13.

    Article  Google Scholar 

  77. Dianatpour A, Ghafouri-Fard S. The role of long non coding RNAs in the repair of DNA double strand breaks. Int J Mol Cell Med. 2017;6:1–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  78. Zhao Z, Mak TK, Shi Y, Huang H, Huo M, Zhang C. The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer. Front Immunol. 2023;14:1117255.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Gencel-Augusto J, Wu W, Bivona TG. Long non-coding RNAs as emerging targets in lung cancer. Cancers (Basel). 2023;15:3135.

    Article  CAS  PubMed  Google Scholar 

  80. Huang C, Azizi P, Vazirzadeh M, Aghaei-Zarch SM, Aghaei-Zarch F, Ghanavi J, Farnia P. Non-coding RNAs/DNMT3B axis in human cancers: from pathogenesis to clinical significance. J Transl Med. 2023;21:621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Qu Y, Tan HY, Chan YT, Jiang H, Wang N, Wang D. The functional role of long noncoding RNA in resistance to anticancer treatment. Ther Adv Med Oncol. 2020;12:1758835920927850.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Takeiwa T, Ikeda K, Horie-Inoue K, Inoue S. Mechanisms of apoptosis-related long non-coding RNAs in ovarian cancer. Front Cell Dev Biol. 2021;9:641963.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Irfan M, Javed Z, Khan K, Khan N, Docea AO, Calina D, Sharifi-Rad J, Cho WC. Apoptosis evasion via long non-coding RNAs in colorectal cancer. Cancer Cell Int. 2022;22:280.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Jiang N, Zhang X, Gu X, Li X, Shang L. Progress in understanding the role of lncRNA in programmed cell death. Cell Death Discov. 2021;7:30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Sadida HQ, Abdulla A, Marzooqi SA, Hashem S, Macha MA, Akil ASA, Bhat AA. Epigenetic modifications: key players in cancer heterogeneity and drug resistance. Transl Oncol. 2023;39:101821.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Raziq K, Cai M, Dong K, Wang P, Afrifa J, Fu S. Competitive endogenous network of lncRNA, miRNA, and mRNA in the chemoresistance of gastrointestinal tract adenocarcinomas. Biomed Pharmacother. 2020;130:110570.

    Article  CAS  PubMed  Google Scholar 

  87. Abhange K, Makler A, Wen Y, Ramnauth N, Mao W, Asghar W, Wan Y. Small extracellular vesicles in cancer. Bioact Mater. 2021;6:3705–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  88. Xu G, Xu W-Y, Xiao Y, Jin B, Du S-D, Mao Y-l, Zhang Z-T. The emerging roles of non-coding competing endogenous RNA in hepatocellular carcinoma. Cancer Cell Int. 2020;20:1–21.

    Article  Google Scholar 

  89. Wang L, Cho KB, Li Y, Tao G, Xie Z, Guo B. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer. Int J Mol Sci. 2019;20:5758.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Wang JJ, Huang YQ, Song W, Li YF, Wang H, Wang WJ, Huang M. Comprehensive analysis of the lncRNA-associated competing endogenous RNA network in breast cancer. Oncol Rep. 2019;42:2572–82.

    CAS  PubMed  PubMed Central  Google Scholar 

  91. Jayarathna DK, Rentería ME, Batra J, Gandhi NS. Integrative competing endogenous RNA network analyses identify novel lncRNA and genes implicated in metastatic breast cancer. Sci Rep. 2023;13:2423.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Du T, Shi Y, Xu S, Wan X, Sun H, Liu B. Long non-coding RNAs in drug resistance of breast cancer. Onco Targets Ther. 2020;13:7075–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Ge X, Yao Y, Li J, Li Z, Han X. Role of LncRNAs in the epithelial-mesenchymal transition in hepatocellular carcinoma. Front Oncol. 2021;11:690800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Cheng J-T, Wang L, Wang H, Tang F-R, Cai W-Q, Sethi G, Xin H-W, Ma Z. Insights into biological role of LncRNAs in epithelial-mesenchymal transition. Cells. 2019;8:1178.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Khanbabaei H, Ebrahimi S, García-Rodríguez JL, Ghasemi Z, Pourghadamyari H, Mohammadi M, Kristensen LS. Non-coding RNAs and epithelial mesenchymal transition in cancer: molecular mechanisms and clinical implications. J Exp Clin Cancer Res. 2022;41:1–20.

    Article  Google Scholar 

  96. Schwerdtfeger M, Desiderio V, Kobold S, Regad T, Zappavigna S, Caraglia M. Long non-coding RNAs in cancer stem cells. Transl Oncol. 2021;14:101134.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Chen S, Zhu J, Wang F, Guan Z, Ge Y, Yang X, Cai J. LncRNAs and their role in cancer stem cells. Oncotarget. 2017;8:110685–92.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol Cancer. 2023;22:172.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Mofed D, Omran JI, Sabet S, Baiomy AA, Emara M, Salem TZ. The regulatory role of long non- coding RNAs as a novel controller of immune response against cancer cells. Mol Biol Rep. 2022;49:11775–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol Med. 2018;24:257–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. He J, Zhu S, Liang X, Zhang Q, Luo X, Liu C, Song L. LncRNA as a multifunctional regulator in cancer multi-drug resistance. Mol Biol Rep. 2021;48:1–15.

    Article  CAS  PubMed  Google Scholar 

  102. Lai XN, Li J, Tang LB, Chen WT, Zhang L, Xiong LX. MiRNAs and LncRNAs: dual roles in TGF-β signaling-regulated metastasis in lung cancer. Int J Mol Sci. 2020;21:1193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Crudele F, Bianchi N, Astolfi A, Grassilli S, Brugnoli F, Terrazzan A, Bertagnolo V, Negrini M, Frassoldati A, Volinia S. The molecular networks of microRNAs and their targets in the drug resistance of colon carcinoma. Cancers (Basel). 2021;13:4355.

    Article  CAS  PubMed  Google Scholar 

  104. Witte S, Muljo SA. Integrating non-coding RNAs in JAK-STAT regulatory networks. Jakstat. 2014;3:e28055.

    PubMed  PubMed Central  Google Scholar 

  105. Hjazi A, Obaid RF, Ali SS, Abdullaev B, Alsaab HO, Huldani H, Romero-Parra RM, Mustafa YF, Hussien BM, Saadoon SJ. The cross-talk between LncRNAs and JAK-STAT signaling pathway in cancer. Pathol Res Pract. 2023;248:154657.

    Article  CAS  PubMed  Google Scholar 

  106. Wang Q, Feng J, Tang L. Non-coding RNA related to MAPK signaling pathway in liver cancer. Int J Mol Sci. 2022;23:11908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Kang Y. Landscape of NcRNAs involved in drug resistance of breast cancer. Clin Transl Oncol. 2023;25:1869.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Dai F, Dai L, Zheng X, Guo Y, Zhang Y, Niu M, Lu Y, Li H, Hou R, Zhang Y. Non-coding RNAs in drug resistance of head and neck cancers: a review. Biomed Pharmacother. 2020;127:110231.

    Article  CAS  PubMed  Google Scholar 

  109. Zhang M, Wang Y, Jiang L, Song X, Zheng A, Gao H, Wei M, Zhao L. LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway. J Exp Clin Cancer Res. 2021;40:1–14.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Romeo M, Dallio M, Scognamiglio F, Ventriglia L, Cipullo M, Coppola A, Tammaro C, Scafuro G, Iodice P, Federico A. Role of non-coding RNAs in hepatocellular carcinoma progression: from classic to novel clinicopathogenetic implications. Cancers (Basel). 2023;15:5178.

    Article  CAS  PubMed  Google Scholar 

  111. Mabeta P, Hull R, Dlamini Z. LncRNAs and the angiogenic switch in cancer: clinical significance and therapeutic opportunities. Genes (Basel). 2022;13:152.

    Article  CAS  PubMed  Google Scholar 

  112. Achkar NP, Cambiagno DA, Manavella PA. miRNA biogenesis: a dynamic pathway. Trends Plant Sci. 2016;21:1034–44.

    Article  CAS  PubMed  Google Scholar 

  113. Zarkou V, Galaras A, Giakountis A, Hatzis P. Crosstalk mechanisms between the WNT signaling pathway and long non-coding RNAs. Non-coding RNA Res. 2018;3:42–53.

    Article  CAS  Google Scholar 

  114. Poursheikhani A, Abbaszadegan MR, Kerachian MA. Mechanisms of long non-coding RNA function in colorectal cancer tumorigenesis. Asia Pac J Clin Oncol. 2021;17:7–23.

    Article  PubMed  Google Scholar 

  115. Riquelme I, Pérez-Moreno P, Mora-Lagos B, Ili C, Brebi P, Roa JC. Long non-coding RNAs (lncRNAs) as regulators of the PI3K/AKT/mTOR pathway in gastric carcinoma. Int J Mol Sci. 2023;24:6294.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi MASB, Hushmandi K, Aref AR, Ashrafizadeh M, Zarrabi A. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling. Biomed Pharmacother. 2022;150:112963.

    Article  CAS  PubMed  Google Scholar 

  117. Li Z, Qian J, Li J, Zhu C. Knockdown of lncRNA-HOTAIR downregulates the drug-resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Exp Ther Med. 2019;18:435–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  118. Schwarzenbach H, Gahan PB. Interplay between LncRNAs and microRNAs in Breast Cancer. Int J Mol Sci. 2023;24:8095.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Zhan H, Tu S, Zhang F, Shao A, Lin J. MicroRNAs and long non-coding RNAs in c-Met-regulated cancers. Front Cell Dev Biol. 2020;8:145.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Yao ZT, Yang YM, Sun MM, He Y, Liao L, Chen KS, Li B. New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer. Cancer Commun (Lond). 2022;42:117–40.

    Article  PubMed  Google Scholar 

  121. Chen R, Yang M, Huang W, Wang B. Cascades between miRNAs, lncRNAs and the NF-κB signaling pathway in gastric cancer (Review). Exp Ther Med. 2021;22:769.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Ahmad S, Abbas M, Ullah MF, Aziz MH, Beylerli O, Alam MA, Syed MA, Uddin S, Ahmad A. Long non-coding RNAs regulated NF-κB signaling in cancer metastasis: micromanaging by not so small non-coding RNAs. Semin Cancer Biol. 2022;85:155–63.

    Article  CAS  PubMed  Google Scholar 

  123. Liu X, Shao Y, Zhou J, Qian G, Ma Z. Nuclear factor κB signaling and its related non-coding RNAs in cancer therapy. Mol Ther Nucl Acids. 2020;19:208–17.

    Article  CAS  Google Scholar 

  124. Zhang Y, Shao J, Li S, Liu Y, Zheng M. The crosstalk between regulatory non-coding RNAs and nuclear factor kappa B in hepatocellular carcinoma. Front Oncol. 2021;11:775250.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Sweef O, Zaabout E, Bakheet A, Halawa M, Gad I, Akela M, Tousson E, Abdelghany A, Furuta S. Unraveling therapeutic opportunities and the diagnostic potential of microRNAs for human lung cancer. Pharmaceutics. 2023;15:2061.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, Liu Z, Xu Q, Liu S, Xiao D, Tao Y. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020;19:47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Zhou M, Liu L, Wang J, Liu W. The role of long noncoding RNAs in therapeutic resistance in cervical cancer. Front Cell Dev Biol. 2022;10:1060909.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Wang W-T, Han C, Sun Y-M, Chen T-Q, Chen Y-Q. Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. 2019;12:1–15.

    Article  Google Scholar 

  129. Zhang Hd, Jiang Lh, Sl Z, Li J, Dw S, Jc H, Wang D, Sy Z, Tang J. The role of long non-coding RNAs in drug resistance of cancer. Clin Genet. 2021;99:84–92.

    Article  CAS  PubMed  Google Scholar 

  130. Castro-Muñoz LJ, Ulloa EV, Sahlgren C, Lizano M, La Cruz-Hernández D, Contreras-Paredes A. Modulating epigenetic modifications for cancer therapy. Oncol Rep. 2023;49:1–23.

    Article  Google Scholar 

  131. Ramassone A, Pagotto S, Veronese A, Visone R. Epigenetics and microRNAs in cancer. Int J Mol Sci. 2018;19:459.

    Article  PubMed  PubMed Central  Google Scholar 

  132. Dai M, Liu M, Yang H, Küçük C, You H. New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities. Exp Hematol Oncol. 2022;11:1–10.

    Google Scholar 

  133. Ghafouri-Fard S, Hajiesmaeili M, Shoorei H, Bahroudi Z, Taheri M, Sharifi G. The impact of lncRNAs and miRNAs in regulation of function of cancer stem cells and progression of cancer. Front Cell Dev Biol. 2021;9:696820.

    Article  PubMed  PubMed Central  Google Scholar 

  134. Asadzadeh Z, Mansoori B, Mohammadi A, Aghajani M, Haji-Asgarzadeh K, Safarzadeh E, Mokhtarzadeh A, Duijf PH, Baradaran B. microRNAs in cancer stem cells: biology, pathways, and therapeutic opportunities. J Cell Physiol. 2019;234:10002–17.

    Article  CAS  PubMed  Google Scholar 

  135. Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A, Pathak C. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep (Hoboken). 2022;5:e1291.

    Article  CAS  PubMed  Google Scholar 

  136. Liu R, Chen Y, Liu G, Li C, Song Y, Cao Z, Li W, Hu J, Lu C, Liu Y. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;11:797.

    Article  PubMed  PubMed Central  Google Scholar 

  137. Ashrafizaveh S, Ashrafizadeh M, Zarrabi A, Husmandi K, Zabolian A, Shahinozzaman M, Aref AR, Hamblin MR, Nabavi N, Crea F. Long non-coding RNAs in the doxorubicin resistance of cancer cells. Cancer Lett. 2021;508:104–14.

    Article  CAS  PubMed  Google Scholar 

  138. Di Vito NM, Vecchiotti D, Flati I, Verzella D, Di Padova M, Alesse E, Capece D, Zazzeroni F. EV-mediated chemoresistance in the tumor microenvironment: is NF-κB a player? Front Oncol. 2022;12:933922.

    Article  Google Scholar 

  139. Si X, Zang R, Zhang E, Liu Y, Shi X, Zhang E, Shao L, Li A, Yang N, Han X. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget. 2016;7:81452.

    Article  PubMed  PubMed Central  Google Scholar 

  140. Usman RM, Razzaq F, Akbar A, Farooqui AA, Iftikhar A, Latif A, Hassan H, Zhao J, Carew JS, Nawrocki ST. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. Asia Pac J Clin Oncol. 2021;17:193–208.

    Article  PubMed  Google Scholar 

  141. Wang G, Wang JJ, Tang HM, To SST. Targeting strategies on miRNA-21 and PDCD4 for glioblastoma. Arch Biochem Biophys. 2015;580:64–74.

    Article  CAS  PubMed  Google Scholar 

  142. Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenetics. 2019;11:1–24.

    Article  Google Scholar 

  143. Brozovic A. The relationship between platinum drug resistance and epithelial–mesenchymal transition. Arch Toxicol. 2017;91:605–19.

    Article  CAS  PubMed  Google Scholar 

  144. Viedma-Rodríguez R, Baiza-Gutman L, Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz Esparza-Garrido R, Velázquez-Flores MA, Arenas-Aranda D. Mechanisms associated with resistance to tamoxifen in estrogen receptor-positive breast cancer. Oncol Rep. 2014;32:3–15.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The author would like to thank the Deanship of Scientific Research at Shaqra University for supporting this work

Funding

This study was supported by Shaqra University.

Author information

Authors and Affiliations

  1. Department of Medical Laboratory Techniques, Al-Maarif University College, Al-Anbar, Iraq

    Raed Obaid Saleh

  2. Department of Microbiology, College of Medicine, University of Anbar, Ramadi, Anbar, Iraq

    Mushtak T. S. Al-Ouqaili

  3. College of Chemistry, Al-Zahraa University for Women, Karbala, Iraq

    Eyhab Ali

  4. Department of Medical Laboratories, College of Applied Medical Sciences, Shaqra University, 11961, Shaqra, Saudi Arabia

    Sharif Alhajlah

  5. College of Health and Medical Technology, Al-Ayen University, Thi-Qar, 64001, Iraq

    Anaheed Hussein Kareem

  6. Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq

    Maha Noori Shakir

  7. College of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq

    Mohammed Qasim Alasheqi

  8. Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq

    Yasser Fakri Mustafa

  9. College of Technical Engineering, The Islamic University, Najaf, Iraq

    Ahmed Alawadi

  10. College of Technical Engineering, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq

    Ahmed Alawadi

  11. College of Technical Engineering, The Islamic University of Babylon, Babylon, Iraq

    Ahmed Alawadi

  12. College of Technical Engineering, Imam Ja’afar Al‐Sadiq University, Al‐Muthanna, 66002, Iraq

    Ali Alsaalamy

Authors
  1. Raed Obaid Saleh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mushtak T. S. Al-Ouqaili
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eyhab Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sharif Alhajlah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anaheed Hussein Kareem
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maha Noori Shakir
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mohammed Qasim Alasheqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yasser Fakri Mustafa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ahmed Alawadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ali Alsaalamy
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MTSAO, EA, AHK, MNS, MGA: Conceptualization, Writing—original draft preparation. YFM, AA(Ahmed Alawadi), AA(Ali Haslany): Conceptualization, Writing—review & editing, Visualization. ROS, SA: Conceptualization, Supervision. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Raed Obaid Saleh or Sharif Alhajlah.

Ethics declarations

Competing interests

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saleh, R.O., Al-Ouqaili, M.T.S., Ali, E. et al. lncRNA-microRNA axis in cancer drug resistance: particular focus on signaling pathways. Med Oncol 41, 52 (2024). https://doi.org/10.1007/s12032-023-02263-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-023-02263-8

Keywords

Search

Navigation